SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-029913
Filing Date
2022-10-31
Accepted
2022-10-31 08:05:27
Documents
12
Period of Report
2022-10-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 70467
  Complete submission text file 0001493152-22-029913.txt   246857

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lctx-20221028.xsd EX-101.SCH 3236
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lctx-20221028_lab.xml EX-101.LAB 34240
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lctx-20221028_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3630
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 221343831
SIC: 2836 Biological Products, (No Diagnostic Substances)